RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
Figure 1
Mean BMD percent changes from baseline in lumbar spine and total hip sites. Results are reported as least-square means of BMD at the lumbar spine and total hip. All values are significantly greater in the denosumab group than the placebo group (P ≤ 0.001) [9].
